Calidi Biotherapeutics, Inc. Operating Lease, Payments
Calidi Biotherapeutics, Inc. (CLDI) reported Operating Lease, Payments of $752.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $380.00K, a 3.26% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $372.00K, a 2.76% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $368.00K, a 3.37% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $369.00K, a 2.22% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating lease, payments for fiscal 2025 was $1.47M, a 3.02% increase from fiscal 2024.
- Calidi Biotherapeutics, Inc. operating lease, payments for fiscal 2024 was $1.42M, a 19.04% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. operating lease, payments for fiscal 2023 was $1.76M, a 100.57% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. operating lease, payments for fiscal 2022 was $877.00K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $380.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $752.00K 10-Q · filed 2026-08-13 | $1.12M derived: sum of 3 quarters · filed 2026-08-13 | $1.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $372.00K 10-Q · filed 2026-05-14 | $740.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.11M derived: sum of 3 quarters · filed 2026-05-14 | $1.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $737.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.10M derived: sum of 3 quarters · filed 2026-08-13 | $1.47M 10-K · filed 2026-03-27 |
| 2025-09-30 | $369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $737.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.10M 10-Q · filed 2025-11-13 | $1.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $730.00K 10-Q · filed 2026-08-13 | $1.09M derived: sum of 3 quarters · filed 2026-08-13 | $1.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $362.00K 10-Q · filed 2026-05-14 | $718.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.08M derived: sum of 3 quarters · filed 2026-05-14 | $1.44M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $717.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.07M derived: sum of 3 quarters · filed 2026-03-27 | $1.42M 10-K · filed 2026-03-27 |
| 2024-09-30 | $361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $719.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.07M 10-Q · filed 2025-11-13 | $1.50M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $358.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $707.00K 10-Q · filed 2025-08-08 | $1.14M derived: sum of 3 quarters · filed 2025-08-08 | $1.46M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $349.00K 10-Q · filed 2025-05-14 | $783.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.10M derived: sum of 3 quarters · filed 2025-05-14 | $1.77M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $754.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.42M derived: sum of 3 quarters · filed 2025-03-31 | $1.76M 10-K · filed 2025-03-31 |
| 2023-09-30 | $320.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $986.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.32M 10-Q · filed 2024-11-12 | $2.09M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $666.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.00M 10-Q · filed 2024-08-13 | $1.77M derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $339.00K 10-Q · filed 2024-05-14 | $1.10M derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $763.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $877.00K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $114.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |